Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

1,177

Participants

Timeline

Start Date

November 6, 2015

Primary Completion Date

January 24, 2023

Study Completion Date

January 21, 2026

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

OTHER

Placebo

IV infusion

All Listed Sponsors

collaborator

ETOP

UNKNOWN

collaborator

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

lead

Merck Sharp & Dohme LLC

INDUSTRY